TL16: Best practices in next-generation sequencing methodology with impact on high-dimensional findings
*Justin Wade Davis, AbbVie Keywords: pharmacogenetics, genomics, next generation sequencing, RNA-Seq, bioinformatics Next generation sequencing (NGS) is the core technology that has made high-throughput genetic and genomic studies possible, and in turn has greatly impacted the field of pharmacogenetics and pharmacogenomics. NGS is rapidly replacing many competing techniques and becoming mature enough for wide-spread research use in industry with many applications (e.g., RNA-Seq). The software and computational tools used in the analysis of such data are much more diverse (and arguably complex) than the sequencing techniques and wet bench protocols used to produce the data. With that diversity, there are many analysis "degrees of freedom" that underlie the statistical and bioinformatic workflow. At this roundtable, we will discuss what tools are being used and what steps have the greatest impact on the end result, based on empirical studies and user experience. More consensus in this area would improve the reliability, reproducibility, and confidence with which findings arising from NGS can used in discovery, development, and ultimately to support regulatory decision making.
|
Key Dates
-
June 3, 2014 - September 7, 2015
Online Registration -
June 3, 2015 - August 15, 2015
Housing -
July 31 - August 17, 2015
Invited Abstract Editing -
August 10, 2015
Short Course materials due from Instructors -
August 26, 2015
Advanced Registration Deadline -
September 7, 2015
Cancellation Deadline -
September 16 - 18, 2015
Marriott Wardman Park, Washington, DC